Download Ottawa Heart Conferences 2016 - University of Ottawa Heart Institute

OTTAWA HEART CONFERENCES 2016
&
Ottawa Heart Conferences 2016
4th Annual Ottawa Heart
Research Conference
(June 2–3)
19
19thth International
International
Toronto-Ottawa
Toronto-Ottawa Heart
Heart
Summit
Summit (June
(June 3–4)
3–4)
Steadying the Future of Atrial Fibrillation
In
In partnership
partnership with
with the
the
Eastern
Eastern Ontario
Ontario
Cardiovascular
Cardiovascular
Summit
Summit XV
XV
EASTERN ONTARI O
CARDIOVASCULAR
JU N E 2 – 4 , 2 016
SHAW CENTRE, OTTAWA
The Shaw Centre, 55 Colonel By Drive,i Ottawa | www.ottawaheart.ca/ohc2016
SUMMIT
2016
OTTAWA HEART CONFERENCES 2016
Sponsors
Appreciation is expressed to the following in support of the Ottawa
Heart Conferences 2016:
PLATINUM PATRONS
GOLD PATRONS
SUPPORTERS
Conference Partners
EASTERN ONTARI O
4
CARDIOVASCULAR
th
ANNUAL OTTAWA HEART
RESEARCH CONFERENCE
SUMMIT
2016
Heart & Stroke Richard Lewar
Centre of Excellence in Cardiovascular Research
ii
OTTAWA HEART CONFERENCES 2016
Contents
Welcome Message . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2
Steering Committee . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
Program Agendas . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
Program Directors . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
Faculty Biographies (OHRC) . . . . . . . . . . . . . . . . . . . . . . 13
Faculty Biographies (TOHS & EOCS) . . . . . . . . . . . . . . . . . 27
Faculty Disclosures (OHRC) . . . . . . . . . . . . . . . . . . . . . . 42
Faculty Disclosures (TOHS & EOCS) . . . . . . . . . . . . . . . . . 43
Accreditation Statement . . . . . . . . . . . . . . . . . . . . . . . . 45
1
OTTAWA HEART CONFERENCES 2016
Welcome Message
Dear Everyone,
The only Constant in Medicine is the Need for Change.
The pace of change in medicine has accelerated in recent times because of our rapidly
evolving patient demographics, dramatic system changes, new quality-based funding
in Ontario, and research and innovation pushing the frontiers of knowledge.
To integrate the latest research, innovations in guidelines and tools, with the evolving
practice landscape, we have partnered three major cardiovascular conferences this
year. We are delighted that the joint steering committee has put together a superb
program and welcome you to join us at the Shaw Centre Ottawa.
On June 2nd and 3rd, the 4th Annual Ottawa Heart Research Conference will feature
state of art advances in research, treatment, and prevention of atrial fibrillation (AF).
The afternoon of June 3rd and on June 4th, The 19th Toronto Ottawa Heart Summit, in
partnership with the Eastern Ontario Cardiovascular Summit XV, will bring together
the most exciting advances in cardiovascular disease and related multidisciplinary
conditions, from treatment to prevention, and innovation to application.
This year’s meeting will offer the opportunity for all of our colleagues to come
together with the goals to bring innovation, evidence, and experience to the frontline
of patient care. The 2016 program features the best quality faculty, the latest topics,
together with an engaged audience to provide a rich opportunity for the exchange
of ideas, conduct discussions, and a debate to maximize interaction. There have been
important advances in these special areas, and we are delighted to provide this unique
opportunity for the faculty, health providers, trainees, and health systems decision
makers to engage the high-calibre international experts in bringing research to clinical
applications.
We are grateful to our perennial conference sponsors for their unconditional support.
We extend to you the heartiest welcome to Ottawa, and we look forward to your active
participation and suggestions for even more exciting future meetings!
Sincerely,
David Birnie, MD
Michael Farkouh, MD
Michael Froeschl, MD
Peter Liu, MD
2
OTTAWA HEART CONFERENCES 2016
Steering Committee
Overall conference chair & chair
of Toronto-Ottawa Heart Summit
(TOHS) subcommittee:
Other steering committee
members:
Dr. Peter Backx (OHRC)
Senior Scientist, York University
Dr. Peter Liu
Chief Scientific Officer and Vice
President of Research, University of
Ottawa Heart Institute
Dr. Mark Fraser (OHRC/TOHS/EOCS)
Fellow of the College of Family
Physicians;
Active Staff at the Queensway
Carleton Hospital;
Co-Lead Physician of the West
Carleton Family Health
Ottawa Heart Research Conference (OHRC) subcommittee chair:
Dr. David Birnie
Staff Cardiac Electrophysiologist;
Director of the Arrhythmia Services;
Director of Clinical Research, Division
of Cardiology, University of Ottawa
Heart Institute;
Associate Professor, University of
Ottawa
Dr. Bradley Strauss (TOHS)
Senior Scientist, Sunnybrook
Research Institute;
Professor, Department of Medicine,
University of Toronto
Dr. Anthony Tang (OHRC)
Staff Electrophysiologist;
Chair of Cardiovascular Population
Health, London Health Science
Centre;
Scientific Director, Canadian
Arrhythmia Network (CANet);
Professor of Medicine, University of
Western Ontario
Toronto Ottawa Heart Summit
subcommittee co-chair:
Dr. Michael Farkouh
Peter Munk Chair in Multinational
Clinical Trials;
Director, Heart and Stroke Richard
Lewar Centre of Excellence;
Professor of Medicine, University of
Toronto
Dr. Atul Verma (TOHS)
Staff Electrophysiologist,
York Clinical Cardiology and
Metabolism, Southlake Regional
Health Centre
Eastern Ontario Cardiovascular
Summit (EOCS) chair:
Dr. Michael Froeschl
Interventional Cardiologist,
University of Ottawa Heart Institute;
Assistant Professor, University of
Ottawa
3
OTTAWA HEART CONFERENCES 2016
Ottawa Heart Research Conference (OHRC):
Steadying the Future of Atrial Fibrillation
Program Agenda
Thursday, June 2nd (Day 1)
7:00 am
Registration and Breakfast
8:00 am
Welcome Message
Drs. David Birnie and Thierry Mesana
8:15–9:35 am
Session 1: Exercise, Lifestyle, Obesity, Primary Prevention of Atrial
Fibrillation
Chair: Dr. Calum Redpath
8:15 am
Basic Science Insights into Exercise, Lifestyle, Obesity, Primary Prevention of Atrial
Fibrillation
Dr. Peter Backx, York University
8:35 am
Aggressive Risk Factor Modification to Reduce Atrial Fibrillation: Is the Evidence
Conclusive?
Dr. Ratika Parkash, Dalhousie University
8:55 am
Can Exercise Improve Quality of Life in Patients with Permanent Atrial
Fibrillation?
Dr. Jennifer Reed, University of Ottawa Heart Institute
9:15 am
Panel Discussion
9:35–10:55 am Session 2: Rotors and Atrial Fibrillation/Atrial Remodeling
Chair: Dr. Pablo Nery
9:35 am
The Atrial Remodeling Determinants of Rotor Dynamics
Dr. Stanley Nattel, Montreal Heart Institute
9:55 am
Initiation and Maintenance of Rotors in Atrial Fibrillation
Dr. José Jalife, University of Michigan
10:15 am
Mapping and Ablating Rotors in the Electrophysiology Lab: Where are we and
Where are we Going?
Dr. Damian Redfearn, Queen’s University
10:35 am
Panel Discussion
10:55 am
Health Break
11:15–12:35
pm
Session 3: Genetics/Biomarkers/miRNA
Chair: Dr. Robert Lemery
11:15 am
Personalizing Care for Atrial Fibrillation: The Promise of Gene-Guided Strategies
Dr. Jason Roberts, University of Western Ontario
11:35 am
Novel Approaches to Preventing Atrial Fibrillation Progression
Dr. Stanley Nattel, Montreal Heart Institute
4
OTTAWA HEART CONFERENCES 2016
Early Detection of the Atrial Fibrillation Substrate
Dr. Peter Liu, University of Ottawa Heart Institute
12:15 pm
Panel Discussion
12:35 pm
Lunch
1:35–2:35 pm
Professor Martin Green Keynote Lecture:
Stroke Risk Reduction in Atrial Fibrillation: Past, Present and Future
Professor Gregory Lip, University of Birmingham
2:35 pm
Health Break
2:50–4:00 pm
Session 4: Key Clinical Research Directions in Atrial Fibrillation
Chair: Dr. Martin Green
2:50 pm
Ten Most Important Atrial Fibrillation Related Stroke Clinical Research
Questions in 2016: C-SPIN and More
Dr. Jeff Healey, McMaster University
3:10 pm
CANet: Canada’s Opportunity to Become World Leader in Atrial Fibrillation
Clinical Research
Dr. Anthony Tang, University of Western Ontario
3:30 pm
Panel Discussion
3:50 pm
Day 1 Concluding Remarks
Dr. David Birnie
4:00 pm
Adjournment
OHRC/Toronto-Ottawa Heart Summit (TOHS) &
Eastern Ontario Cardiovascular Summit (EOCS)
Friday, June 3rd (Day 2)
7:00 am
Registration and Breakfast
8:00 am
Official Welcome and Introduction
Drs. Peter Liu and Michael Farkouh
8:15–9:35 am
Session 1: Ablation for Atrial Fibrillation (Who, How and When)
Chair: Dr. David Birnie
8:15 am
Current Perspectives and Future Directions
Dr. Hugh Calkins, Johns Hopkins Hospital
8:45 am
Ablation of Persistent Atrial Fibrillation
Dr. Atul Verma, Southlake Regional Health Centre
9:15 am
Panel Discussion
5
Program Agenda
11:55 am
OTTAWA HEART CONFERENCES 2016
9:35–10:55 am Session 2: Stroke Reduction in Atrial Fibrillation: Update for the Clinician
Chair: Dr. David Birnie
9:35 am
Recent Updates from the Canadian Guidelines
Dr. Allan Skanes, University of Western Ontario
10:05 am
Controversial Areas in Atrial Fibrillation
Dr. Hugh Calkins, Johns Hopkins Hospital
10:35 am
Panel Discussion
10:55 am
Health Break
Program Agenda
TOHS & EOCS
11:15–12:55
pm
Session 3: Heart Failure
Chair: Dr. Peter Liu
11:15 am
Role of LCZ696 in Contemporary Treatment of HFrEF and HFpEF: Present and Future
Dr. Kirkwood Adams, University of North Carolina at Chapel Hill
11:35 am
New Roles of ARNI or LCZ696 in HFpEF or Post MI Remodeling and Beyond
Dr. Peter Liu, University of Ottawa Heart Institute
11:55 am
Guiding Treatment of Heart Failure with Biomarkers
Dr. Alan Maisel, VA San Diego Healthcare System
12:15 pm
Personalizing Therapy for Heart Failure—Heart Rate as a Biomarker?
Dr. Peter Liu, University of Ottawa Heart Institute
12:35 pm
Panel Discussion
12:55 pm
Lunch
2:00 pm
Keynote Lecture: End-of-life Care in Cardiac Patients
Dr. Christopher Simpson, Queen’s University
2:30–4:10 pm
Session 4: Acute Coronary Syndrome & Cardiac Critical Care
Chair: Dr. Michael Froeschl
2:30 pm
What to Know about CTO
Dr. Bradley Strauss, Sunnybrook Health Sciences Centre
2:50 pm
Antiplatelet Therapy after Percutaneous Coronary Intervention—
Understanding the ACC/AHA Guidelines
Dr. Derek So, University of Ottawa Heart Institute
3:10 pm
Critical Appraisal of Target Temperature Management in Out-of-hospital
Cardiac Arrest
Dr. Michel Le May, University of Ottawa Heart Institute
6
OTTAWA HEART CONFERENCES 2016
Chest Pain Syndromes and Patient Engagement
Dr. Michael Froeschl, University of Ottawa Heart Institute
3:50 pm
Active Learning Q & A with Panel
4:10 pm
Health Break
4:25–6:00 pm
Session 5: Recent Advances in Cardiovascular Management
Chair: Dr. Thierry Mesana
4:25 pm
TAVI Update and Implications
Dr. Thierry Mesana, University of Ottawa Heart Institute
4:45 pm
Aortic Diseases – Who, When, What, How?
Dr. Munir Boodhwani, University of Ottawa Heart Institute
5:05 pm
Promising Diagnostic to Direct Heart Failure Management:
The IMAGE-Heart Failure Trial
Dr. Robert Beanlands, University of Ottawa Heart Institute
5:25 pm
Active Learning Q & A with Panel
5:45 pm
Adjournment
Saturday, June 4th (Day 3)
7:00 am
Registration and Breakfast
8:00 am
Official Welcome and Introduction
Drs. Peter Liu and Michael Farkouh
8:10 am
Keynote Lecture: Primary Care and Use of High Sensitivity Troponins–Here they Come!
Dr. Alan Maisel, VA San Diego Healthcare System
8:30–9:50 am
Session 6: Diabetes
Chair: Dr. Michael Farkouh
8:30 am
SGLT2 Inhibitors and CVD in Diabetes: The EMPA-REG OUTCOME Trial
Dr. Bernard Zinman, University of Toronto
8:50 am
Liraglutide, a New LEADER in Type 2 DM Management?
Dr. Michael Farkouh, University of Toronto
9:10 am
Renal Implications of Diabetes Treatment
Dr. Kim Connelly, St. Michael’s Hospital
9:30 am
Active Learning Q & A with Panel
9:50 am
Health Break
10:20–11:50
am
Session 7: Atherosclerosis
Chair: Dr. Jacob Udell
10:20 am
Can we Pacify Atherosclerosis by Novel Anti-inflammatory Approaches?
Dr. Jacob Udell, University of Toronto
7
Program Agenda
3:30 pm
Program Agenda
OTTAWA HEART CONFERENCES 2016
10:40 –11:20
am
DEBATE on PCSK9: All High Risk Patients with Residual Elevation of LDL Should
be on PCSK9 Inhibitors
Pro—Dr. John Mancini, University of British Columbia
Con—Dr. Ruth McPherson, University of Ottawa Heart Institute
11:20 –11:40
am
Rebuttal
Dr. John Mancini, University of British Columbia
Dr. Ruth McPherson, University of Ottawa Heart Institute
11:40 am
Active Learning Q & A with Panel
12:00 pm
Lunch
1:00–2:20
pm
Session 8: Risk Intervention
Chair: Dr. Ruth McPherson
1:00 pm
State-of-the-Art in Hypertention Control: Can we still SPRINT after HOPE-3?
Dr. Sheldon Tobe, Sunnybrook Health Sciences Centre
1:20 pm
Exercise Interventions for Patients with Heart Disease: What’s New? What’s
Promising?
Dr. Robert Reid, University of Ottawa Heart Institute
1:40 pm
Early Atherosclerosis Imaging: Detection and Risk Interpretation
Dr. Girish Dwivedi, University of Ottawa Heart Institute
2:00 pm
Active Learning Q & A with Panel
2:20–3:20
pm
Session 9: Challenges in Managing the Geriatric Population
Chair: Dr. Sheldon Tobe
2:20 pm
Frailty as a New Risk Factor for Chronic Cardiovascular Risk?
Dr. Sheldon Tobe, Sunnybrook Health Sciences Centre
2:40 pm
Geripardy! The Answer is: “What is Geriatrics?”
Dr. Allen Huang, University of Ottawa
3:00 pm
Active Learning Q & A with Panel
3:20 pm
Adjournment and light refreshments
8
OTTAWA HEART CONFERENCES 2016
Program Directors
David Birnie, MB, ChB, MRCP, MD
Clinician Investigator, Staff Cardiac Electrophysiologist,
Chair in Electrophysiology Leadership;
Director, Arrhythmia Service;
Director, Clinical Research, Division of Cardiology,
University of Ottawa Heart Institute;
Mid-Career Investigator, Heart and Stroke Foundation;
Associate Professor, Division of Cardiology, Department of Medicine
University of Ottawa
Dr. David Birnie received his medical degree (MB ChB) from Glasgow University in 1990. After completion
of Internal Medical training at Aberdeen University he gained his MRCP (UK) in 1993. He spent three
years as a cardiology research fellow at Glasgow University from 1993 studying the immunology of
atherosclerosis and was awarded his PhD equivalent (MD) in 1996. Between 1996 and 2001 he undertook
cardiology training at Glasgow University and received his Certificate of Completion of Specialist
Cardiology Training in 2001. In addition he spent a year in 1999-2000 as a Cardiac Electrophysiology Fellow
at the University of Ottawa Heart Institute. Dr. Birnie was recruited to the University of Ottawa Heart
Institute in 2002 as staff cardiac electrophysiologist and clinician investigator.
Dr. Birnie is a founding and current member of the Canadian Heart Rhythm Society Research Committee.
He is chair of the first international guidelines for the diagnosis and management of cardiac sarcoidosis. He
currently sits on both Canadian Institutes of Health Research (CIHR) and Heart and Stroke Foundation peer
review panels.
Since 2013, Dr. Birnie, as principal investigator, has been awarded grants from the Heart and Stroke
Foundation of Canada and is a recipient of the Heart and Stroke Foundation Ontario (HSFO) Mid Career
Investigator Award, where his application was ranked no.1 in the competition. He plays a leading role as
Co-Principal Investigator on the CIHR Canadian Atrial Fibrillation Stroke Prevention Network and in the
NCE Canadian Arrhythmia Network (CANet). Dr. Birnie has previously been funded by the British Heart
Foundation, HSFC, CIHR and the JP Bickell Foundation.
Dr. Birnie is the Director of the Arrhythmia Service at UOHI. His clinical focus is on all aspects of cardiac
electrophysiology including arrhythmia pharmacotherapy and radiofrequency ablation of simple and
complex arrhythmias including atrial fibrillation. He also has a major clinical interest in all aspects of
implantation and follow-up of device therapy for arrhythmias. This includes pacemakers, implantable
cardioverter defibrillators (ICD) and cardiac resynchronization therapy (CRT).
Dr. Birnie’s major ongoing research interests are selection and optimization of CRT for heart failure
patients, investigating optimal strategies for stroke reduction around device surgery and cardiac
sarcoidosis.
9
OTTAWA HEART CONFERENCES 2016
Michael E. Farkouh, MD, FRCPC, MSc, FACC, FAHA
Peter Munk Chair in Multinational Clinical Trials, University Health Network;
Director of the Heart and Stroke / Richard Lewar Centre of Excellence in
Cardiovascular Research;
Professor and Vice-Chair, Research, Department of Medicine, University of
Toronto
Dr. Michael E. Farkouh is a graduate of the Schulich School of Medicine at Western University. Dr. Farkouh
completed his internal medicine and cardiology training at the Mayo Clinic and the Icahn School of
Medicine at Mount Sinai New York respectively and holds an MSc in Clinical Epidemiology from McMaster
University.
Prior to his current appointments, Dr. Farkouh served as the founding director of the Mount Sinai
Cardiovascular Clinical Trials Unit in New York City. He has published over 200 papers largely on acute
coronary syndromes and cardiovascular prevention. He has mentored numerous international residents
and fellows and is active in teaching clinical research methodology.
Dr. Farkouh is internationally known for his work on the management of acute coronary syndromes in the
emergency room. He has a special interest and expertise in the field of cardiovascular disease in diabetic
patients. He is currently the project officer for numerous clinical trials on questions related to diabetes and
heart disease including the NIH-sponsored FREEDOM trial and coordinates clinical studies in Grenada and
Colombia. He chairs the committee on diabetes and heart disease at the Banting and Best Centre and at
the University of Toronto.
Dr. Farkouh has received the Gold Medal from John Paul II Hospital in Krakow, was elected Teacher of the
Year at the Mayo Clinic, and was awarded the Jan J. Kellermann Memorial Award from the International
Academy of Cardiology.
10
OTTAWA HEART CONFERENCES 2016
Michael Froeschl, MD, MSc, FRCPC, FACC
Director of Education, Division of Cardiology, University of Ottawa
Dr. Froeschl received his bachelor’s degree from Harvard University and his medical degree from McGill
University. His clinical training includes three years at the University of Toronto in internal medicine
and four years at the University of Ottawa Heart Institute—three in adult cardiology and a fourth in
interventional cardiology. He joined the Division of Cardiology at the University of Ottawa in 2006. Dr.
Froeschl’s chief academic interest is medical education. In 2011, he completed a master’s degree in
health professions education at Maastricht University in the Netherlands, supported by the Royal College
of Physicians and Surgeons of Canada Fellowship for Studies in Medical Education. He was appointed
Director of the Adult Cardiology Residency Training Program at the University of Ottawa in 2013, and in
2015, he was appointed Director of Education for the Division of Cardiology.
11
OTTAWA HEART CONFERENCES 2016
Peter Liu, MD, FRCPC
Chief Scientific Officer/ Vice President , Research
University of Ottawa Heart Institute;
Director, Cardiac Function Laboratory
University of Ottawa Heart Institute;
Professor, Faculty of Medicine, University of Ottawa;
Professor, Faculty of Medicine, University of Toronto.
Dr. Liu joined the Heart Institute as the Scientific Director in 2012. He received his M.D. and completed his
postgraduate training in Internal Medicine and Cardiology at University of Toronto and Harvard Medical
School.
Formerly, as the inaugural Director of the Heart & Stroke/Richard Lewar Centre of Excellence at the
University of Toronto, Dr. Liu successfully fostered collaboration amongst researchers from various
institutions, while increasing the impact of publications. Subsequently as Scientific Director of the
Institute of Circulatory and Respiratory Health at the Canadian Institutes of Health Research (CIHR), Dr. Liu
launched national networks in imaging, clinical trials and knowledge translation and fostered national
and international research networks. Dr. Liu has designed the Ottawa region cardiovascular research
strategy (ORACLE) and is implementing it in stages. Dr. Liu also directs several large-scale national and
international research programs.
Dr. Liu has been recognized with numerous awards, including both the Research Achievement Award and
the Life Time Achievement Award of the Canadian Cardiovascular Society, the Rick Gallop Award of the
Heart & Stroke Foundation, and the Institute of Circulatory & Respiratory Health Distinguished Lecture
Award of CIHR, and the Margolese Award from UBC, amongst others.
Well known for his contributions to heart failure and cardiac inflammation research, Dr. Liu discovered
how viruses can enter the myocardium and trigger inflammation, and how innate and acquired immunity
contribute to cardiac remodeling and heart failure progression following injury. His laboratory currently
focuses on innovative proteomic biomarkers to detect early and personalize treatment for cardiac diseases,
and elucidate novel mechanisms of disease.
Dr. Liu is also interested in knowledge translation, having harmonized and simplified the major national
guidelines using a novel evidence-based consensus approach (C-CHANGE program), and finding ways to
maximize knowledge translation globally using innovative technologies.
12
OTTAWA HEART CONFERENCES 2016
Faculty Biographies (OHRC)
Peter Backx, PhD
Senior Scientist, York University
Dr. Backx bio ...
Hugh Calkins, MD
Professor of Cardiology
Director of Electrophysiology
Nicholas J. Fortuin MD, Professor of Cardiology
Johns Hopkins Medical Institutions
Past President, The Heart Rhythm Society
Professor of Medicine
Dr. Hugh Calkins is an internationally recognized expert on catheter ablation, atrial fibrillation, syncope,
arrhythmogenic right ventricular dysplasia (ARVD) and arrhythmia management.
Dr. Calkins attended Williams College and Harvard Medical School before training in medicine at
Massachusetts General Hospital. He received his cardiology training at Johns Hopkins. His first faculty
position was at the University of Michigan, where he directed the Pacemaker Service, and he returned to
Johns Hopkins as director of the Arrhythmia Service in 1992.
Dr. Calkins is an Associate Editor of the Journal of Cardiovascular Electrophysiology and is on the editorial
board of many other cardiology journals. He is a former member of the American Board of Internal
Medicine Electrophysiology Boards Test Writing Committee. Dr. Calkins is a fellow of the American College
of Cardiology, the American Heart Association and the Heart Rhythm Society. He led a 44-member
13
OTTAWA HEART CONFERENCES 2016
international task force whose 2012 Expert Consensus Statement gave recommendations for treatment
and research of atrial fibrillation. Dr Calkins is a past president of the Heart Rhythm Society and was
elected to be a member of the Miler Coulsen Academy of Clinical Excellence in 2014.
Dr. Calkins has published more than 500 articles and book chapters on a large variety of cardiac
arrhythmias. His research has focused predominantly on catheter ablation, atrial fibrillation, syncope, and
arrhythmogenic right ventricular dysplasia. Dr. Calkins has also written extensively on most aspects of
heart rhythm disorders and their treatment.
Robert Lemery, MD
Staff Electrophysiologist,
University of Ottawa Heart Institute
Martin Green, MD, FRCPC
Cardiologist, University of Ottawa Heart Institute;
Professor, Department of Medicine, University of Ottawa
Dr. Green graduated from the Faculty of Medicine at the University of Toronto in 1975, at which time he
was awarded the KJR Wightman Award in Internal Medicine and the Cody Silver Medal. He trained in
Internal Medicine at the University of Ottawa, becoming a Fellow of the Royal College of Physicians and
Surgeons of Canada (FRCPC) in Medicine and in Cardiology.
He then travelled to Maastricht, the Netherlands, to further his training in Cardiac Electrophysiology under
the direction of Professor Hein J. J. Wellens as a Fellow of the Medical Research Council of Canada. Dr.
Green returned to Ottawa to start the Arrhythmia Service in 1983.
14
OTTAWA HEART CONFERENCES 2016
Jeff Healey, MD, FRCPC
Principal Investigator, Arrhythmia Program,
Population Health Research Institute;
Associate Professor, McMaster University;
Director of Arrhythmia Services, Hamilton Health Sciences;
Chair, Canadian Stroke Prevention Intervention Network (C-SPIN)
Jeff Healey is the director of arrhythmia services and associate professor of medicine at McMaster
University. He is also a clinical trialist, and member of the Population Health Research Institute. Dr. Healey
completed his clinical training in cardiology and electrophysiology at the University of Ottawa Heart
Institute and completed his Master’s degree in health research methodology at McMaster University.
Currently, Dr. Healey’s clinically activities involve both catheter ablation and pacemaker/ICD implantation.
His research involves the conduct of randomized clinical trials and large registries in the fields of cardiac
arrhythmias and cardiac devices. His area of research focus is studying the effect of risk factors, and risk
factor modification on the development of atrial fibrillation and its complications, such as stroke.
Dr. Healey was the lead author of the ASSERT trial, which was published in the New England Journal
of Medicine in 2012 and demonstrated the increased stroke risk associated with sub-clinical atrial
fibrillation detected by pacemakers. Thomson-Reuters recognized ASSERT as the 38th most-cited scientific
publication in 2012 (#16 in Medicine).
Dr. Healey has published over 280 manuscripts and abstracts, including 60 manuscripts in the past 2
years (24 as first or last author). Dr. Healey has received numerous grants from the Canadian Institutes of
Health Research, the Heart and Stroke Foundation and from industry. He is the co-chair of the Canadian
Cardiovascular Society’s Atrial Fibrillation Guidelines Committee, co-chair of the CCS Guidelines for
Perioperative management of pacemakers and defibrillators and past chair of the Cardiac Care Network of
Ontario’s Heart Rhythm Working group.
Dr. Healey is the principal investigator and chair of the Canadian Stroke Prevention Intervention Network
(C-SPIN), a ten-year network grant funded by the Canadian Institutes of Health Research, The Heart and
Stroke Foundation of Canada and Industry. CSPIN will conduct a series of clinical trials related to atrial
fibrillation and stroke prevention and will also support the development of new Canadian researchers in
this field.
15
OTTAWA HEART CONFERENCES 2016
José Jalife, MD
Cyrus and Jane Farrehi Professor of Cardiovascular Research;
Professor of internal medicine and molecular and integrative physiology,
University of Michigan Medical School;
Co-director of the University of Michigan Center for Arrhythmia Research
Dr. Jalife completed his MD at the Universidad Nacional Autónoma de México in 1972. After clinical
training in Spain, he moved to the United States to work as a postdoctoral fellow at the Upstate Medical
Center in Syracuse, NY, and the Masonic Medical Research Laboratory in Utica, NY. He joined the
Department of Pharmacology, Upstate Medical University, as a member of the faculty in 1980 and became
its Chairman in 1988. In January of 2008, he was recruited by the University of Michigan to his present
position as Professor of Internal Medicine and the Cyrus and Jane Farrehi Professor of Cardiovascular
Research and Professor of Molecular & Integrative Physiology.
Dr. Jalife enjoys an international reputation as a leader in the study of cardiac arrhythmias. His work has
increased the understanding of the fundamental mechanisms of atrial fibrillation, ventricular tachycardia/
fibrillation and sudden cardiac death. He has published more than 320 original papers and review articles,
and has edited/authored fifteen books, including the internationally acclaimed Cardiac Electrophysiology:
From Cell to Bedside, now in its sixth edition. Dr. Jalife has served the US National Institutes of Health
in many capacities, including past membership in Research Committee-A, the Cardiology Advisory
Committee, the Cardiovascular Study Section, (CVA), and the ESTA Study Section of the National Heart
Lung and Blood Institute. He has also been a member of multiple site visit committees and ad-hoc review
committees of the NHLBI and the American Heart Association.
Throughout his career Dr. Jalife has trained more than 100 scientists for research careers at nearly all
educational levels, including pre-doctoral fellow for PhD degrees, medical student, post-doctoral trainees,
medical residents and clinical fellows. In 2001 Dr. Jalife was awarded the Distinguished Scientist Award
of the American College of Cardiology. Other accolades include the Distinguished Scientist Award of the
Heart Rhythm Society, the Lucian Award for Research in Circulatory Diseases from McGill University, the
President’s Award for Research at SUNY Upstate Medical University, the Professor Pierre Rijlant Award
from the Académie Royale de Médecine de Belgique in Brussels, Belgium, the State University of New York
Chancellor’s Award for Excellence in Scholarship and Creative Activities, the Mirowski Award of Excellence
in the field of Clinical Cardiology and Electrophysiology and the Arthur C. Guyton Distinguished Lecturer
ward from the Association of Chairs of Departments of Physiology. Dr. Jalife is an honorary member of
the Mexican National Academy of Medicine, Fellow of the American Heart Association, Fellow of the
Heart Rhythm Society and member of the Association the American Association of Physicians; between
2010 and 2012 he served as President of the Cardiac Electrophysiology Society. In 2015 he was awarded a
Doctor Honoris Causa by the University of Valencia in Spain.
16
OTTAWA HEART CONFERENCES 2016
Gregory YH Lip, MD, FRCPC, DFM, FACC, FESC
Institute of Cardiovascular Sciences
Consultant Cardiologist and Professor of Cardiovascular Medicine
Director – Haemostasis Thrombosis & Vascular Biology Unit
University of Birmingham Centre for Cardiovascular Sciences
Professor Lip is a member of the European Heart Rhythm Association (EHRA) and Chairs its scientific
documents committee (2013-). He serves on the board of the Working Group on Thrombosis of
the European Society of Cardiology (ESC). He is a member of the Working Group on Cardiovascular
Pharmacology of the ESC, and is also a member of the European Association of Percutaneous Coronary
Revascularisation.
Professor Lip has acted as Clinical Adviser for the UK National Institute for Health & Clinical Excellence
(NICE) guidelines on atrial fibrillation (AF) management (2006), and part of the Guideline Development
Group for the 2014 NICE guidelines on AF. He was also on the writing committee for the 8th American
College of Chest Physicians (ACCP) Antithrombotic Therapy Guidelines for Atrial Fibrillation, as well as
various guidelines and/or position statements from EHRA including the EHRA statement on defining
endpoints for AF management and EHRA guidelines for antithrombotic therapy during ablation.
He has acted as Chair for task forces, writing a EHRA/Working Group on Thrombosis Position Statement on
Bleeding Risks in Atrial Fibrillation Patients (2011), as well as joint consensus document of the ESC Heart
Failure Association and Working Group Thrombosis on Thromboembolism and Antithrombotic Therapy for
Heart Failure in Sinus Rhythm (2012).
Professor Lip was Chairman of the Task Force which developed and launched a new EHRA patient
information webpage (www.afibmatters.org), launched June 2013.
He was also on the writing committee of the 2010 ESC Guidelines on Atrial Fibrillation, the 2012 ESC
Focused Update Guidelines on Atrial Fibrillation, and the 2012 ESC Guidelines on Heart Failure. He was
Deputy Editor (“content expert”) for the 9th ACCP guidelines on antithrombotic therapy for AF (2012).
Professor Lip has acted as Senior Editor for major international textbooks [eg, Lip GYH, Hall JE (eds)
Comprehensive Hypertension. Mosby 2007] and Section Editor on hypertension (eg, Crawford, DiMarco,
PaulusCardiology, now in 3rd edition), as well as contributed to major textbooks [eg, the European
Textbook of Cardiovascular Medicine (chapter on atrial fibrillation that serves as the core curriculum for
ESC cardiology trainees), and Crawford’s Cardiology textbook chapter on atrial fibrillation, etc.
Professor Lip is involved at the senior editorial level for major international journals, including Thrombosis
& Haemostasis (Editor-in-Chief, Clinical Studies - Impact Factor 6.094); Europace (Associate Editor);
andCirculation (Guest Editor). Under his editorship, Thrombosis and Haemostasis was winner of the
Thomson Reuters ScholarOne Journal Triathlon, an international award given to the publication which
shows efficiency, longevity and validation of submissions (issued December 2013)
17
OTTAWA HEART CONFERENCES 2016
Professor GYH Lip MD has research interests in atrial fibrillation, hypertension, heart failure, thrombosis
and antithrombotic therapy, and ethnic differences in vascular disease. In addition, he has a major interest
into the psychophysiology and understanding of the disease process in cardiovascular disease (including
atrial fibrillation), as well as physician and patient perceptions of antithrombotic management strategies.
Finally, he leads a laboratory-based research group into thrombosis and vascular biology in cardiovascular
disease and stroke.
Thierry Mesana, MD, PhD
President and CEO, University of Ottawa Heart Institute;
Cardiac Surgeon, University of Ottawa Heart Institute;
Professor, Cardiac Surgery, University of Ottawa.
A native of France, Dr. Mesana is recognized as one of the leading heart valve surgeons in the world. He
received his medical degree at the Université de la Méditerranée, Marseille, France, where he trained
in thoracic and cardiovascular surgery. He received his PhD in biophysics and biomechanics at the same
university after extensive experimental work on artificial hearts and ventricular assist devices.
Dr. Mesana’s specialty interests include adult cardiac surgery, valvular heart disease, mitral valve
repair, surgery of thoracic aorta and aortic dissection, and surgery of heart failure, including heart
transplantation, ventricular assist devices, and cardiomyoplasty.
He is recognized as one of the world’s leading heart valve surgeons, with specific emphasis in mitral
valve repair. His leadership led to significant changes in the Division of Cardiac Surgery at the University
of Ottawa Heart Institute, with the rapid development of complex and innovative mitral valve repair
techniques in degenerative or ischemic disease, and the development of surgical ablation for atrial
fibrillation.
He has also strongly supported and contributed to research in myocardial regeneration and endothelial
stem cells. His group in Ottawa has published extensive studies related either to basic research in
angiogenesis or to clinical research into long-term follow-up of patients with heart valve prostheses.
These include studies on aortic prosthesis mismatch, predictors of long-term outcome, such as stroke,
heart failure, mitral valve prosthetic mismatch, tissue valve durability, and re-operation rates.
Dr. Mesana has been directly involved in most of the research projects in the Division of Cardiac Surgery.
18
OTTAWA HEART CONFERENCES 2016
Stanley Nattel, MD
Professor of Medicine and Paul-David Chair in Cardiovascular Electrophysiology, University of Montreal;
Cardiologist and Director, Electrophysiology Research Program, Montreal
Heart Institute;
Editor-in-Chief, Canadian Journal of Cardiology
Dr. Nattel received his MD in 1974, Internal Medicine and Clinical Pharmacology training between 1974
and 1978 (McGill), and Cardiology clinical and research training (Indiana University and University of
Pennsylvania 1978-1981) before joining the faculty at McGill in 1981. In 1987, he transferred to the
Montreal Heart Institute, where he directed the Research Center between 1990 and 2004. He is presently
Paul-David Chair in Cardiovascular Electrophysiology at the University of Montreal. He is Editor in Chief of
the Canadian Journal of Cardiology, Associate Editor of Heart Rhythm, Cardiovascular Research and Journal
of Physiology, and is on the editorial board of 12 other journals. His research focuses on clinically-relevant
mechanisms of cardiac bioelectricity, particularly atrial fibrillation, proarrhythmia, cardiac remodeling,
ion channel molecular physiology and mechanisms of drug action. His lab uses a wide range of molecular,
cellular, whole-animal and theoretical methods to gain insights into clinically-relevant basic mechanisms
and identify novel therapeutic targets.
Dr Nattel’s area of research is basic mechanisms of cardiac electrical activity and arrhythmias, with a
particular interest in cardiac ion channel function, atrial fibrillation and novel, mechanistically-based
therapeutic approaches.
Pablo Nery, MD
Staff Cardiac Electrophysiologist, University of Ottawa Heart Institute;
Associate Professor, Faculty of Medicine, University of Ottawa
Dr. Nery is a cardiac electrophysiologist specialized in the treatment of complex cardiac arrhythmias.
His major clinical interest is radio-frequency ablation for atrial fibrillation and ventricular tachycardia. He
has a particular interest in the diagnosis and management of patients with cardiac sarcoidosis.
Dr. Nery’s research interests are directly linked to his clinical expertise. He is actively involved in research
studies assessing innovative catheter ablation strategies for the treatment of atrial fibrillation and
ventricular tachycardia.
19
OTTAWA HEART CONFERENCES 2016
Ratika Parkash , MD, FRCPC
Division of Cardiology (Arrhythmia), QE II Health Sciences Center;
Professor of Medicine, Dalhousie University
Dr. Ratika Parkash is an outcomes and clinical trials researcher in atrial fibrillation and cardiac implantable
electrical devices. Dr. Parkash was previously Chair of the Canadian Heart Rhythm Society Device
Committee and, as such, led research on Riata (St Jude Medical) in Canada. The retrospective survey on
Riata was accepted for publication in Heart Rhythm in 2013.
Dr. Parkash research foci include Atrial fibrillation – mechanisms of disease, clinical trials, management
strategies and Cardiac Implantable Electronic devices – device recalls, management, outcomes,
complications.
She has received the following awards and recognitions: Greg Ferrier Award, 2006 and 2013, awarded
to highest ranked Heart and Stroke Foundation of Canada Grant in Nova Scotia, Award of Merit Grand
Rounds, Department of Medicine 2011; Young Investigator Award 2006; Community of Scholars Excellence
in Research 2008; CIHR Randomized Clinical Trials Mentoring Award 2008-2010; Research grants from
CIHR, HSFC and Nova Scotia Health Research Foundation, Cardiac Arrhythmia Network (CANet).
20
OTTAWA HEART CONFERENCES 2016
Damian Redfearn, MB ChB MD MRCPI FRCPC
Associate Professor, Department of Medicine
Department of Biomedical and Molecular Sciences,
School of Medicine, Queen’s University
Dr Redfearn is a cardiologist specialising in electrophysiology, the treatment of arrhythmia. His has
particular expertise in catheter ablation of complex arrhythmia. He holds a doctorate degree in Medicine
and is cross-appointed with the School of Computing and the Department of Biomedical and Molecular
Sciences. He is the Director of the Heart Rhythm Service at Kingston General Hospital.
His research interests include catheter ablation and improved non-invasive diagnostic tools through
enhanced ECG interpretation. His research lab focuses on novel algorithm development and electrogram
analysis. Clinical work includes optimal RV lead placement in CRT.
Calum Redpath, MD, PhD
Clinician-Scientist and Staff Cardiologist,
University of Ottawa Heart Institute;
Assistant Professor, Department of Medicine,
University of Ottawa
Dr. Redpath received undergraduate medical training in Glasgow, Scotland and was awarded membership
of the Royal College of Physicians & Surgeons of Glasgow (MRCP) in 2000. The work of his PhD studied
human cellular cardiac electrophysiology. He joined the Heart Institute in 2010.
Dr. Redpath’s research focuses on the prevention, detection and treatment of all arrhythmia-related
disorders with a special interest in atrial fibrillation. His research interests span from single atrial cells all
the way to population based studies and are primarily aimed at a greater understanding of arrhythmia
mechanisms, with particular focus on atrial fibrillation.
21
OTTAWA HEART CONFERENCES 2016
Jennifer Reed, PhD
Associate Scientist, Division of Prevention and Rehabilitation;
Director, Exercise Physiology and Cardiovascular Health Lab,
University of Ottawa Heart Institute;
Part-Time Professor, Faculty of Health Sciences, University of Ottawa
Dr. Reed received her BA and BPHE from Queen’s University in 2005, and Master of Education in Coaching
Science (MEd CS) from the University of Victoria in 2007. She later earned her PhD in Kinesiology, with a
specialty in exercise physiology and women’s health, from The Pennsylvania State University in 2012.
In 2013, she joined the Division of Prevention and Rehabilitation at the University of Ottawa Heart
Institute as a Postdoctoral Research Fellow. In her current position as an Associate Scientist, her overall
research program focuses on the role of exercise and nutritional strategies in cardiovascular disease
prevention and rehabilitation as well as women’s health.
In 2013, Dr. Reed was awarded the Jan & Ian Craig Cardiac Prevention and Rehabilitation Endowed
Fellowship from the University of Ottawa Heart Institute. She was also awarded the Harold F. Martin
Graduate Assistant Outstanding Teaching Award (2011) and Research Fellowships (2008-2011) from the
Pennsylvania State University.
22
OTTAWA HEART CONFERENCES 2016
Jason D. Roberts, MD
Assistant Professor of Medicine
Schulich School of Medicine, Western University;
Cardiac Arrhythmia Service, London Health Sciences Centre
Jason Roberts assumed the role of Clinical Cardiac Electrophysiologist and Assistant Professor of Medicine
at Western University in London, Ontario, Canada in August, 2015. He completed his training in cardiac
electrophysiology at the University of California, San Francisco (UCSF) during a 3 year fellowship that also
included a year of dedicated research. During this period, he obtained a Master’s Degree in Epidemiology
and Biostatistics from UCSF. He completed his Cardiology Fellowship at the University of Ottawa Heart
Institute, his Internal Medicine Residency at the University of Toronto, and Medical School at Memorial
University.
As a clinician scientist, his research centers on the genetics of cardiac arrhythmias. During his training in
Ottawa, he worked in the laboratory of Dr. Michael Gollob and studied the genetics of atrial fibrillation
and inherited arrhythmia syndromes, including the short QT syndrome. He also worked with Dr. Derek So
and Spartan Bioscience to develop a point-of-care genetic test for clopidogrel, the results of the clinical
trial being subsequently published in the Lancet. In London, his research program is focused on all aspects
of arrhythmia genetics with a particular emphasis on gene discovery and pharmacogenomic applications.
23
OTTAWA HEART CONFERENCES 2016
Allan Skanes, MD, FRCPC
Professor, Department of Medicine
Schulich School of Medicine & Dentistry
The University of Western Ontario
Dr. Allan Skanes is currently the Director of the Electrophysiology Laboratory at the London Health
Sciences Centre, University Hospital, London, Ontario, Canada, and an Associate Professor of Medicine at
Western University.
He received his medical degree in 1990 from the University of Toronto where he also completed his
Internal Medicine training. He completed his Cardiology and Electrophysiology training at the University
of Ottawa Heart Institute before a research fellowship in Syracuse New York, investigating the underlying
mechanisms of arrhythmia, especially atrial fibrillation.
The Electrophysiology Laboratory, a busy interventional program with an active and productive research
program, is a current clinical user of state of the art imaging and navigation technologies. Dr. Skanes,
Director, is an experienced electrophysiologist and clinician scientist with a specific interest in nonpharmacologic therapy for arrhythmia, remote and non-fluoroscopic catheter navigation and catheter
ablation of cardiac arrhythmia. He is uniquely skilled to evaluate clinical utility of imaging and tracking
technologies, image-modality compatible tools, as well as fusion of device representations with maps of
anatomy and function.
Most recently, he co-chaired the 2010 Canadian Cardiovascular Society management guidelines for atrial
fibrillation as well as the 2012 Focused Update. He is actively researching novel non-fluoroscopic catheter
navigation technologies in animal models, as well as human studies. His research contributes clinical
relevance and applicability to development of navigation and guiding technologies. It also provides
unique experience and skill set, as well as environment for further translational development to human
studies.
He has published 144 peer-reviewed papers and 10 book chapters.
24
OTTAWA HEART CONFERENCES 2016
Anthony Tang, MD, FRCPC
Professor, Department of Medicine
Schulich School of Medicine & Dentistry
The University of Western Ontario
Dr. Anthony Tang is Professor of Medicine at Western University and Adjunct Professor of Medicine in the
Faculty of Medicine at the University of Ottawa. Dr. Tang is presently Staff Electrophysiologist, Division
of Cardiology, London Health Science Centre and Chair of Cardiovascular Population Health. He obtained
his MD from the University of Toronto and his clinical training in Internal Medicine and Cardiology
at the University of Ottawa. Dr. Tang obtained a Heart and Stroke Research Fellowship to receive
electrophysiology research training at Duke University Medical Centre. He is member of the Ontario
Medical Association, American College of Cardiology (Fellow), Canadian Cardiovascular Society, Heart
Rhythm Society (Fellow), and American Heart Association.
Dr. Tang’s clinical and research expertise is on the diagnosis and treatment of patients with cardiac
arrhythmia, particularly in heart failure patients. He has conducted multi-national, multicentre clinical
trials in the last 15 years. The research on the addition of CRT to Implantable Cardioverter Defibrillator
(ICD) and medical therapy demonstrated a reduction of total mortality and hospitalization for Heart
Failure (HF) in ambulatory heart failure patients. (NEJM 2010;363(25):2385-95). This study results
changed the treatment strategy of heart failure patients with compromized LV function and electrical
dyssynchrony. Dr. Tang currently has two CIHR grants to conduct research that examines treatment
options for patients in atrial fibrillation with heart failure. Currently, he is the Scientific Director for the
Canadian Arrhythmia Network (CANet), which is funded by the Network of Excellence (NCE) from 2015-20.
Dr. Tang is an internationally renowned researcher, has been an invited speaker at national and
international meetings, and is a peer reviewer for scientific journals, as well as grant reviewer for Heart
and Stroke and Canadian Institute of Health Research. His publication record includes over 140 peer
reviewed papers, 5 book chapters and over 270 abstracts.
25
OTTAWA HEART CONFERENCES 2016
Atul Verma, MD, FRCPC
Director, Heart Rhythm Program, Southlake Regional Health Centre;
Assistant Professor, Division of Cardiology, University of Toronto
Dr. Atul Verma received his MD degree from the University of Toronto and completed his residency in
internal medicine and cardiology there as well. He is a fellow of the Royal College of Physicians and
Surgeons of Canada in both internal medicine and cardiology. He has also been certified by the American
Board of Internal Medicine in cardiovascular medicine & cardiac electrophysiology. He is currently an
assistant professor with McGill University.
Dr. Verma specializes in cardiac electrophysiology, with practice in ablation techniques, percutaneous
biventricular and basic device implantation, and in the diagnosis and management of cardiac arrhythmia
and device problems. In particular, Dr. Verma trained at the Cleveland Clinic in the ablation of complex
rhythm disorders such as atrial fibrillation and ventricular tachycardia. His research interests and activities
include the evaluation of novel catheter-based technologies and cardiac imaging techniques, and in
clinical database research and clinical trial design, with a current focus on comparing different catheterbased ablation techniques for arrhythmia control.
He has authored or co-authored over 120 articles and abstracts on electrophysiology issues, ablation,
and arrhythmia for such journals as the New England Journal of Medicine, Circulation, The Journal of the
American College of Cardiology, Heart, The Journal of Cardiovascular Electrophysiology, The American
Journal of Cardiology, and The Canadian Journal of Cardiology. Dr. Verma has received many honors and
awards during his career including being a Heart and Stroke Foundation of Canada Research Fellowship
awardee (2003-05), which is a peer-reviewed award for two years of funding for electrophysiology
research.
Dr. Verma has helped draft several national and international guidelines including the CCS Atrial
fibrillation guidelines.
26
OTTAWA HEART CONFERENCES 2016
Faculty Biographies (TOHS & EOCS)
Kirkwood Adams, MD
Associate Professor of Medicine and Radiology,
University of North Carolina at Chapel Hill
Dr. Kirkwood F. Adams Jr., is Associate Professor of Medicine and Radiology in the Division of Cardiology,
University of North Carolina at Chapel Hill, where he founded and for many years directed the UNC Heart
Failure Program and served as the first transplant cardiologist for two decades, helping to establish this
treatment at UNC.
Dr. Adams has been involved in more than 130 completed grant- and industry-funded research projects,
and he is currently leading or participating in five drug development trials, several registry and database
studies, and continues to be involved in NIH/NHLBI-funded trials. Dr. Adams is the principal investigator
for the national multicenter database group, UNITE-HF, which focuses on registries of patients with heart
failure. He has published more than 175 manuscripts in refereed journals, a number of book chapters and
monographs, and more than 150 abstracts.
Dr. Adams served as chair of the Guidelines/Clinical Positions Committee of the Heart Failure Society of
America from 1996 to 2006 and is a past member of the Executive Council of this society. In addition
to drug development for acute and chronic heart failure, his current research interests are heavily
focused on personalized medicine with ongoing projects related to novel biomarkers for heart failure,
pharmacogenomics of heart failure therapeutics, and biomarker guided therapy for improving outcomes
in CHF. He is very actively involved on the Executive Committee for the NHLBI sponsored trial of NTproBNP
guided therapy known as the GUIDE-IT Trial.
27
OTTAWA HEART CONFERENCES 2016
Robert Beanlands, MD
Vered Chair and Chief of Cardiology,
Director, National Cardiac PET Centre,
Director, Molecular Function and Imaging Program,
Clinician Scientist; University of Ottawa Heart Institute;
Professor, Division of Cardiology, Department of Medicine,
Professor, Department of Radiology (Cross-Appointment),
Professor, Department of Cellular and Molecular Medicine
(Cross-Appointment), University of Ottawa Faculty of Medicine Research
Chair Award (Tier 1) in Cardiovascular Disease, University of Ottawa
Dr. Rob Beanlands is the Chief and Vered Chair of the Division of Cardiology at the University of Ottawa
Heart Institute. He received his MD from the University of Ottawa in 1983 (gold medalist). He is an
international leader in cardiovascular nuclear imaging and the founding Director of the Heart Institute’s
National Cardiac PET Centre, the only PET facility in Canada dedicated to cardiovascular disease. He
is a Career Investigator supported by the Heart and Stroke Foundation and holds the Tier 1 Chair in
Cardiovascular Imaging Research (uOttawa). His research focus on the heart’s metabolism, flow and
cellular function has led to pioneering translational work that has impacted the understanding of disease
mechanisms, applications in patient care, health policy and guidelines in imaging. He has led several
multicentre imaging research initiatives [PARR2, IMAGE-HF, CADRE Registry and is a Co-PI for the Canadian
Atherosclerotic Imaging Network (CAIN)]. He has more than 225 peer reviewed publications in this
field. He has served on several committees/advisory boards for government, industry and professional
organizations impacting healthcare policies and practice guidelines and serves as an Associate Editor
for the Canadian Journal of Cardiology and the Journal of Nuclear Cardiology. He is a Professor in the
Faculty of Medicine, Department of Radiology and Department of Cellular and Molecular Medicine at
the University of Ottawa. Dr. Beanlands is past-president of the Canadian Nuclear Cardiology Society,
past Ontario Governor for the American College of Cardiology and was the Scientific Program Chair and
Annual Meeting Chair for the Canadian Cardiovascular Society. He is also the chair of the Heart and Stroke
Foundation Scientific Review Committee, Treasurer of the American Society of Nuclear Cardiology and CoChair of the International Congress on Nuclear Cardiology and CT imaging. Recent Awards include Queen
Elizabeth II Diamond Jubilee Medal (2012) for Contributions to Canada, Hermann Blumgart Research
Achievement Award for the Society of Nuclear Medicine (2013) and Canadian Cardiovascular Society
Research Achievement Award (2015).
28
OTTAWA HEART CONFERENCES 2016
Munir Boodhwani, MD
Cardiac Surgeon,
University of Ottawa Heart Institute;
Assistant Professor,
University of Ottawa
Dr. Boodhwani earned a BSc with High Distinction from the University of Toronto in 1997 and a medical
degree from the University of Western Ontario in London, Ontario, in 2001. These were followed by a
residency in cardiac surgery at the Heart Institute in 2004. In 2006, he served as a research fellow in
cardiothoracic surgery at Beth Israel Deaconess Medical Center in Boston and earned a Masters in Medical
Sciences from Harvard Medical School.
Dr. Boodhwani has won numerous distinctions and awards. He has served his profession in Trinidad and
Pakistan and has been chair of the Aga Khan Health Board for Ottawa’s Medical Advisory Service.
Dr. Boodhwani’s interests include issues in complex coronary revascularization procedures and arterial
grafting, the polymer-based delivery of endothelial progenitor cells for myocardial regeneration,
cardiopulmonary bypass practices and clinical trials, neurocognitive outcomes following cardiac surgery,
coronary physiology and pharmacology, and the effect of diabetes, hypercholesterolemia, and endothelial
function on myocardial angiogenesis.
29
OTTAWA HEART CONFERENCES 2016
Kim Connelly, PhD
Director, Krembil Stem Cell Facility, St. Michael’s Hospital;
Staff Cardiologist, St. Michael’s Hospital;
Consultant Cardiologist, Sunnybrook Health Science Centre
Dr. Kim Connelly is a Cardiologist and Scientist who is both nationally recognized as an expert in human
and rodent echocardiography, cardiovascular MRI and the impact of diabetes upon cardiac function. His
work has been recognized evident by winning the “Young Investigator of the Year Award” in 2012 by the
Canadian Cardiovascular Society an Early Researcher Award in 2014, a CIHR New Investigator award in
2014 and the SC Verma Young Investigator Award in 2015.
Dr. Connelly runs a basic research laboratory at the Keenan Research Centre at St. Michael’s Hospital where
he focuses upon basic mechanisms of disease – primarily around the role of pathological extracellular
matrix accumulation and the pro-sclerotic cytokine transforming growth factor beta, with a focus upon
translating discoveries into therapies in humans. He is the Director of the Krembil Stem Cell Facility at St.
Michael’s Hospital and uses stem cell based therapies to improve cardiac and renal dysfunction as a result
of diabetes. He collaborates extensively not only locally in Toronto but also nationally and internationally
– with research support from the HSF of Canada, CIHR and CFI along with significant research support
from the pharmaceutical industry.
30
OTTAWA HEART CONFERENCES 2016
Girish Dwivedi, MD, PhD
Cardiologist, University of Ottawa Heart Institute;
Assistant Professor, University of Ottawa
Dr. Dwivedi completed his MD from the University of Delhi, India, in 1998 and his PhD from the University
of Manchester, England, three years later. He then secured one of the most prestigious clinical lectureships
in the United Kingdom, the National Institute of Health Research Clinical Lectureship at the University of
Birmingham, and was awarded the Certificate of Completion of Specialist Training in Cardiology.
He moved to the University of Ottawa Heart Institute in 2011 to obtain further experience in cardiac CT,
SPECT and PET imaging techniques, and was awarded the prestigious CIHR Banting Fellowship. He has
obtained training and accreditation in echocardiography, cardiac MRI, cardiac CT, PET and SPECT. He joined
the staff of the Heart Institute in 2013.
Dr. Dwivedi’s clinical and research interests centre on cardiac imaging, with special emphasis on
inflammation as the cause of atherosclerosis, heart failure and cardiomyopathy, and application of
myocardial contrast echocardiography.
31
OTTAWA HEART CONFERENCES 2016
Allen Huang, MDCM, FRCPC, FACP, AGSF
Chief & Chair, Division of Geriatric Medicine,
University of Ottawa and The Ottawa Hospital;
Associate Professor of Medicine, Faculty of Medicine, University of Ottawa;
Adjunct Professor, Faculty of Medicine, McGill University
Dr. Huang is the Chief and Chair of the Division of Geriatrics. He comes to us from McGill University Health
Centre (MUHC), Montreal, Quebec where he was a former director, Division of Geriatric Medicine and
program director, McGill postgrad residency program in Geriatric Medicine
Research/focus
Health services research: Optimal pharmacotherapy for older adults. Health informatics.
Medical education: time & motion studies. Interprofessional teams.
Awards and Recognition
2003 Qualcomm CDMA-A-List award for Impact, non-profit category. For the MOXXI project & wireless
prescribing.
2006 Prix J.-Armand-Bombardier – Innovation. (ACFAS – Association canadienne-française pour
l’avancement des sciences)
Michel Le May, MD, FRCPC
Interventional Cardiologist,
University of Ottawa Heart Institute
Professor of Medicine,
University of Ottawa
Dr. Le May is an interventional Cardiologist and Professor of Medicine at the University of Ottawa Heart
Institute, as well as the Director of the HOHI Regional STEMI Program.
His primary research focus is on developing novel strategies for the management of acute myocardial
infarction.
Dr. Le May has been the recipient of numerous awards throughout his career, including the Heart
Institute’s inaugural Global Achievement Award in Clinical Leadership in 2015, the Lumen Global
Achievement Award presented by HRH Princess Chulabhorn Walailak of Thailand in 2014, the Top
Achievement CIHR Award in 2009 and was named the Heart Institute Clinical Science Investigator of the Year
in 2008.
32
OTTAWA HEART CONFERENCES 2016
Alan S. Maisel, MD
Professor of Medicine , University of California, San Diego
Director, Coronary Care Unit and Heart Failure Program, Veterans Affairs San
Diego Healthcare System
Dr. Alan S. Maisel graduated from the University of Michigan Medical School, received his internal
medicine training at Michael Reese Hospital in Chicago, where he was chief resident, and completed a
cardiology fellowship at the University of California, San Diego.
Dr. Maisel is a Professor of Medicine at the University of California, San Diego (UCSD). He is the Director
of the Coronary Care Unit and Heart Failure Program at the VA San Diego Healthcare System in La Jolla,
California. Dr. Maisel is active on the faculty at UCSD where he has won numerous teaching awards. He
just completed a ten-year stint as Associate Editor of the Journal of the American College Cardiology
Dr Maisel is considered one of the world’s experts on cardiac biomarkers and has over 400 scientific
publications. He has authored several ground-breaking manuscripts that have paved the way for
development of diagnostic tools for patients with congestive heart failure. In particular, he was the
leading investigator on studies that brought the use of BNP into clinical practice. He has been lead
investigator on seven multicentre biomarker trials.
His recent work on cardiac biomarkers has led to a connection between diet, cardiovascular disease and
breast cancer, and currently works on two biomarkers that predict the development of breast cancer. He
recently co-founded the UCSD Biomarker Research Center, which among other things make data and a
statistician available for research by residents and fellows.
Dr Maisel is also a writer of medical fiction. His first novel, Bedside Manners was optioned to Warner
Brothers. His second novel, Brain Chicane, is about a young and idealistic physician working at the premier
multiple-organ transplant hospital in Chicago where he investigates overdose cases that are not totally
kosher. He is also co-founder of a mitochondrial drug company and a biomarker discovery company.
He is founder of My Life Diagnostics. He is a co-founder of Aceptiscope. He is the primary care-giver for
five children and gave up on sleep five years ago.
33
OTTAWA HEART CONFERENCES 2016
G.B. John Mancini, MD
Cardiology, Vancouver General Hospital;
Professor of Medicine, University of British Columbia;
Director, Cardiovascular Imaging Research Core Laboratory-CIRCL
Dr. G.B. John Mancini is a tenured Professor of Medicine at the University of British Columbia, and
directs an imaging-based research program (Cardiovascular Imaging Research Core Laboratory, CIRCL)
that includes facilities for quantitative coronary angiography, ultrasound analysis (coronaries, carotids
and brachial artery for atherosclerosis and endothelial function assessments) and cardiac computed
tomography analysis. Dr. Mancini remains in active practice as a staff physician in the Vancouver Hospital
Cardiology Outpatient Clinic and the Cardiac Computed Tomography Program, as well as the St. Paul’s
Hospital Healthy Heart Prevention Program/Lipid Clinic.
Dr. Mancini received his MD degree from the University of Toronto, completed his residency at Toronto
General Hospital and was a Cardiology and Research Fellow at the University of California at San Diego.
After a year as Clinical Assistant Professor at U.C. San Diego, he joined the faculty of the University of
Michigan, where he became Associate Chief of Cardiology and Chief of the V.A. Section of Cardiology in
1987. He was Chair of Medicine at the University of British Columbia from 1992 to 2002. He is a Fellow of
the American College of Cardiology, Governor of the American College of Cardiology (British Columbia) and
a member of the Circulation Council of the American Heart Association; he is also a member of numerous
other professional associations in the United States and Canada. Dr. Mancini is a Past President of the
Canadian Society for Clinical Investigation and current President of the Medical/Allied Staff of Vancouver
Hospital. He has published over 250 journal articles, abstracts, books and book chapters. He serves as a
reviewer for many journals, and is currently a member of the editorial boards of the American Journal of
Cardiology, the Canadian Journal of Cardiology and the International Journal of Cardiac Imaging.
Dr. Mancini is currently Coordinating Investigator for the Cardiovascular Imaging Research Core Laboratory
for numerous multi-centred trials. His areas of special interest include digital angiography, quantitative
coronary angiography, quantitative intravascular ultrasound, quantitative carotid ultrasound, cardiac
computed tomography, coronary flow reserve/fractional flow reserve, endothelial dysfunction, primary
and secondary CV risk reduction and regression of atherosclerosis.
34
OTTAWA HEART CONFERENCES 2016
Ruth McPherson, MD, PhD
Merck Frosst Canada Chair in Atherosclerosis Research;
Director, Ruddy Canadian Cardiovascular Genetics Centre;
Director, Atherogenomics Laboratory and Lipid Clinic,
University of Ottawa Heart Institute;
Professor, Departments of Medicine and Biochemistry,
University of Ottawa
Dr. McPherson received her PhD from the University of London, in England, and her MD from the
University of Toronto, where she graduated magna cum laude in 1984. She completed subspecialty
training in Internal Medicine and Endocrinology and Metabolism at the University of Toronto. She held
academic positions at the University of Toronto and McGill University before joining the University of
Ottawa Heart Institute in 1992.
Dr. McPherson is a key opinion leader in Canada in the area of clinical lipidology and cardiovascular risk
reduction. Dr. McPherson has been an author on the several renditions of the Canadian Cardiovascular
Society Position Statement on the Diagnosis and Treatment of Dyslipidemia and Prevention of
Cardiovascular Disease and is a strong advocate of strategies for the primary and secondary prevention
of cardiovascular disease. Dr. McPherson is Associate Editor of Arteriosclerosis, Thrombosis, and Vascular
Biology and is a member on the Editorial Boards of the Canadian Journal of Cardiology, Journal of Lipid
Research, and Circulation – Cardiovascular Genetics.
Dr. McPherson’s research is funded by the Canadian Institutes of Health Research and the Heart and Stroke
Foundation of Canada. She has published over 190 manuscripts in peer-reviewed journals. She is a lead
investigator of the CARDIoGRAM+C4D consortium; her other global partnerships are extensive,including
GIANT, MAGIC, Global Lipids, NHLBI ESP, Diogenes and other networks. She has been a keynote speaker at
a number of international conferences, including the American Heart Association ATVB meeting, Gordon
Conference, International Society of Atherosclerosis and Keystone meeting. Dr. McPherson currently holds
the Merck Frosst Canada Chair in Atherosclerosis. Dr. McPherson’s achievements have been recognized
with a number of awards, including the The Journal of Lipid Research Lectureship Award, ISA XVI, 2012,
AHA Council on Arteriosclerosis, Thrombosis & Vascular Biology. Arteriosclerosis Special Recognition
Award, 2011, International Atherosclerosis Symposium XV 2009: Outstanding Achievement Award. She
was elected a fellow of the Royal Society of Canada in 2014.
Dr. McPherson is a leader in cardiovascular genetics, having led the discovery of the 9p21 genetic risk
factor for heart disease in 2007. Dr. McPherson’s research is centered on the discovery and functional
analysis of genetic variants linked to cardiovascular disease and its metabolic precedents, including lipid
traits and obesity.
35
OTTAWA HEART CONFERENCES 2016
Robert Reid, PhD, MBA
Deputy Chief, Division of Prevention and Rehabilitation,
University of Ottawa Heart Institute;
Professor, Faculty of Medicine,
University of Ottawa
Dr. Reid obtained his PhD in Health Studies at the University of Waterloo in 1997 following an MBA in
Marketing from the University of Ottawa in 1990. He is one of Canada’s leading health behavior change
experts, particularly concerning smoking cessation, physical activity promotion, dietary change and
cardiovascular rehabilitation.
Dr. Reid’s research is funded by the Heart and Stroke Foundation of Canada, the National Cancer Institute
of Canada, the Canadian Tobacco Control Research Initiative, the Ontario Ministry of Health Promotion, the
Change Foundation, and Health Canada.
He is the Canadian Association of Cardiac Rehabilitation 20th Anniversary Research Leadership Award
recipient. He was also awarded the Investigator of the Year (Clinical Science) award in 2011. In addition,
he is a past recipient of the Heart and Stroke Foundation of Canada’s New Investigator Award. In 2009,
he delivered the prestigious 17th Annual Terry Kavanagh Lecture at the Canadian Association of Cardiac
Rehabilitation symposium. In 2006, he was awarded the James Hogg Award from the Canadian Institutes
of Health Research Institute for Circulatory and Respiratory Health for his contributions to clinical and
population health research.
The overall aim of Dr. Reid’s research is to improve the quality and efficiency of chronic disease prevention
and management programs. Over the past 10 years, his research group has focused on three main themes:
1) developing systematic approaches to smoking cessation in clinical practice settings; 2) promoting
exercise and physical activity in patients with heart disease; and 3) examining the effectiveness and
cost-efficiency of different models of delivering primary and secondary prevention services. More recently,
the group has taken on the challenge of how best to reduce risk and prevent heart disease in the family
members of patients with diagnosed heart disease.
36
OTTAWA HEART CONFERENCES 2016
Christopher S. Simpson, MD, FRCPC, FACC, FHRS, FCAHS
Professor of Medicine & Chief of Cardiology, Queen’s University;
Medical Director, Cardiac Program, Kingston General Hospital / Hotel Dieu
Hospital;
Past President, Canadian Medical Association;
Dr. Chris Simpson is Professor of Medicine and Chief of Cardiology at Queen’s University as well as the
Medical Director of the Cardiac Program at Kingston General Hospital / Hotel Dieu Hospital. In 2015, Dr.
Simpson was elected to fellowship in the Canadian Academy of Health Sciences. He is the Past President of
the Canadian Medical Association (CMA).
Dr. Simpson’s primary professional interest is health policy – particularly access to care. He serves as
the Chair of the Wait Time Alliance (WTA) and as Past Chair of the Canadian Cardiovascular Society’s
(CCS) Standing Committee on Health Policy and Advocacy. He was the Lead for the Southeast (Ontario)
Local Health Integration Network (LHIN) Cardiovascular Roadmap Project. He serves on the Cardiac Care
Network of Ontario board of directors, and is a past member of the CCS executive and a former governor of
the American College of Cardiology.
He served as the first President of the Canadian Heart Rhythm Society and was a founding executive
member of the International Coalition of Pacing and Electrophysiology Organizations (COPE). He sits
on numerous editorial boards and advisory committees, and has chaired or been a member of several
national and international consensus conferences, including serving as co-chair of the CCS Consensus
Conference on Medical Fitness to Drive and Fly. He was President of the Canadian Medical Association in
2014-2015 and is a past recipient of the Canadian Medical Association’s Award for Young Leaders.
Dr. Simpson is an active clinician, educator and researcher. He has authored or co-authored over 350
peer-reviewed publications. His clinical and research interests include access to care, medical fitness
to drive, referral pathway development, atrial fibrillation, sudden death in the young, and cardiac
resynchronization therapy.
37
OTTAWA HEART CONFERENCES 2016
Derek So, MD, FRCPC, FACC
Director, Adult Interventional Cardiology Program
University of Ottawa Heart Institute
Associate Professor
University of Ottawa
Dr. Derek So earned his medical degree, cum laude, at the University of Toronto in 1997. He completed
residencies in Internal Medicine at McMaster University in Hamilton, Ontario, and Cardiology at
the University of Ottawa Heart Institute. He then went on to Fellowship training in Interventional
Cardiology at the University of Ottawa Heart Institute. He furthered his training with a Master’s in Clinical
Epidemiology at the Harvard School of Public Health in Cambridge, Massachusetts.
Dr. So’s research interests include: acute coronary syndromes, PCI outcomes, pharmacogenomics and
personalized anti-platelet therapy. Currently, Dr. So is leading a group of basic science and clinical
researchers in the RAPID program, studying future strategies for personalized anti-platelet therapy.
Dr. So has held grants from the Canadian Institute of Health Research (CIHR) and the Heart and Stroke
Foundation (HSF) in the field of anti-platelet therapies. He currently holds a mid-career investigator
award from HSF. As part of the RAPID program, Dr. So presented the RAPID GENE study as a late breaking
trial at the Transcatheter Cardiovascular Therapeutics (TCT) 2011 conference. This study has been
published in The Lancet.
38
OTTAWA HEART CONFERENCES 2016
Bradley Strauss, MD, PhD
Senior Scientist,
Director, Interventional Cardiology Research, Sunnybrook Health Sciences
Centre;
Professor, Department of Medicine,
Professor, Laboratory Medicine and Pathobiology, University of Toronto;
Reichmann Chair, Cardiovascular Sciences,
Sunnybrook Health Sciences Centre and University of Toronto
Dr. Bradley Strauss was born in Kitchener, Ontario, Canada. He obtained his MD cum laude from the
University of Toronto in 1982. He completed his Residency Training in Internal Medicine at the University
of Toronto in 1986 and then a Clinical Fellowship in Cardiology at the University of Ottawa Heart Institute
in 1988. Subsequently he was awarded a Research Fellowship from the Heart and Stroke Foundation to do
research work at the world-famous Thoraxcenter in Rotterdam, the Netherlands under the supervision of
Professor Patrick Serruys. During his time in Rotterdam, he obtained a PhD from Erasmus University for his
work on coronary stenting and the arterial response to stenting injury.
He currently is Chief of the Schulich Heart Program and Head of the Division of Cardiology at Sunnybrook
Health Sciences Centre in Toronto, Canada. He holds the Reichmann Chair in Cardiovascular Research, and
is a Professor of Medicine and Professor of Laboratory Medicine and Pathobiology at the University of
Toronto.
His main clinical activity is interventional cardiology. He is very active in both basic research (arterial
response to injury, angiogenesis) and clinical research related to interventional research and coronary
imaging. He has authored over 170 papers and 18 book chapters and serves on the Editorial Board of
5 journals. His main clinical interest is chronic total occlusions, including studies on pathophysiology,
epidemiology, imaging and development of new chronic occlusion therapies. He has founded a company,
Matrizyme Pharma, to commercialize the use of collagenase to soften the plaque in order to facilitate
guidewire crossing in chronic total occlusions. Matrizyme Pharma has recently completed a Phase 2
Clinical Trial (TOSCA-5) in 11 Canadian centers as well as sites in Israel and the Netherlands.
39
OTTAWA HEART CONFERENCES 2016
Jacob A. Udell, MD, MPH, FRCPC
Cardiovascular Division, Women’s College Hosptial,
Peter Munk Cardiac Centre, Toronto General Hospital
University of Toronto
Dr. Udell is a Cardiologist and clinician-scientist at Women’s College Hospital and the Peter Munk Cardiac
Centre, University Health Network and an Assistant Professor of Medicine at the University of Toronto
with expertise in observational studies, clinical trials, and health services research. His group’s work on
innovative cardiovascular risk factor identification and therapy has led to: clinical trial and outcomes
publications in the New England Journal of Medicine, JAMA, JACC, and Lancet Diabetes and Endocrinology;
alterations in national practice guidelines; and changes by the FDA in the label of saxagliptin. Utilizing
the administrative health care databases, registries, and clinical trial populations at his disposal, Dr. Udell
studies the cardiovascular benefits and risks of new diabetes and antiplatelet therapies and novel risk
factors, including influenza infection. Dr. Udell is a Co-Principal Investigator of the 9300-patient INVESTED
randomized controlled trial, which is investigating the cardiovascular benefit of high-dose versus
standard-dose influenza vaccination. He is a regular Checkup Panel member on CBC TV’s The National
news broadcast discussing timely health topics and the recipient of multiple awards, including a CIHR
Health Services and Policy Research Rising Star Award (2014), a Heart and Stroke Foundation of Canada
National New Investigator/Ontario Clinician Scientist (Phase I) Award (2016), and an Ontario Ministry of
Research and Innovation Early Researcher Award (2016).
40
OTTAWA HEART CONFERENCES 2016
Bernard Zinman, CM MD FRCPC FACP
Director, Leadership Sinai Centre for Diabetes;
Sam and Judy Pencer Family Chair in Diabetes,
Mount Sinai Hospital and University of Toronto;
Professor of Medicine, University of Toronto;
Senior Scientist, Lunenfeld-Tanenbaum Research Institute,
Mount Sinai Hospital
Bernard Zinman completed his medical degree at McGill University, Montreal, Quebec, Canada, and
received further training in endocrinology at the University of Toronto.
Dr Zinman is involved with diabetes care and research at both national and international levels.
His main research interests include the long-term complications of diabetes, the development of new
therapies for type 1 and type 2 diabetes, diabetes in aboriginal communities, and studies directed at the
prevention of diabetes. He is the recipient of numerous awards including the Charles H. Best Medal for
Distinguished Service in the Cause of Diabetes (awarded to the Diabetes Control and Complications Trial
Investigators), the American Diabetes Association Outstanding Physician Clinician Award, the Novartis
Prize for Diabetes, the Lifetime Achievement Award from the Canadian Diabetes Association and notably
Dr Zinman was appointed to the Order of Canada, in recognition of his achievements in diabetes patient
care and research. He is Vice Chair for the Diabetes Control and Complications Trial/Epidemiology of
Diabetes Interventions and Complications (DCCT/EDIC) study. Dr Zinman has authored more than 500
publications in national and international journals, and over 60 book chapters and editorials.
41
OTTAWA HEART CONFERENCES 2016
Faculty Disclosures (OHRC)
Name
Company
Disclosure Details
David Birnie
Bayer, Boehring-Ingelheim
Clinical Trial
Hugh Calkins
Boehringer-Ingleheim
PI Clinical Trial
Medtronic
Consultant
Topera-Abbott Labs
Consult on mechanism of atrial
fibrilation
Medtronic, Inc
Research Grants
Bayer, Janssen, Astellas,
Merck,Sanofi,BMS/Pfizer, Biotronik,
Medtronic, Portola, Boehringer-Ingelheim, Microlife and Daiichi-Sankyo
Consultant
Peter Backx
Jeff Healey
José Jalife
Gregory Lip
Bayer,BMS/Pfizer,Medtronic, Boehringer- Payment from Comm Org
Ingelheim, Microlife, Roche and DaiichiSankyo
Peter Liu
Novartis, Roche, Amgen, Pfizer, Merck,
Janssen
Advisory board
Servier, Roche Diagnostics, Novartis
Grants
Stanley Nattel
Omeicos, Merck, Aptose Pharm
Research Contract, Consulting
Ratika Parkash
St. Jude Medical, Pfizer, Bayer, Medtronic Research Grants
St. Jude Medical, Pfizer
Clinical Trial
Damian Redfearn
Jennifer Reed
Jason Roberts
No disclosures
Allan Skanes
Bayer, Pfizer, Boehringer-Ingelheim
Honoraria (speaking)
Anthony Tang
Medtronic
Research Grant
Medtronic, Jude Medical, Sorin, Arca
Biopharm, Boehringer-Ingelheim
Clinical Trial
Biosense, Medtronic
Advisory Board
Bayer, Biosense, Medtronic
Compensation, Grant
Medtronic, St Jude Medical
Clinical Trial
Atul Verma
42
OTTAWA HEART CONFERENCES 2016
Faculty Disclosures (TOHS & EOCS)
Name
Company
Disclosure Details
Kirkwood Adams
Novartis, Covis, AMGEN, Relypsa
Expert Counsel
Novartis, AMGEN, Covis, Roche
Grant
Novartis, AMGEN, Roche
Clinical Trial
GE Healthcare, Lantheus, Medical
Image, Jubilant DRAXImage
Grant/Honorarium
Boehringer-Ingelheim
PI Clinical Trial
Robert Beanlands
Munir Boodhwani
Hugh Calkins
Kim Connelly
Medtronic
Consultant
Astra Zeneca, B-I,Merck, Servier,
Janssen
Advisory Board or Equivalent
Astra Zeneca, B-I,Merck, Servier
Grants/Honorarium
B-I
Patent
B-I, Servier
Clinical Trial
Girish Dwivedi
Michael Farkouh
No disclosures
Amgen, Servier
Grant / Honorarium
Michael Froeschl
No disclosures
Allen Huang
No disclosures
Michel Le May
No disclosures
Peter Liu
See Faculty Disclosures (OHRC 2016)
Alan Maisel
Critcal DX, AdrenoMed
Advisory Board or equivalent:
Modest Stipend
Alere, Abbott, Critical DX, Siemens
received payment for talks
Alere, Abbott, Critical DX, Siemens
Grants/Honorarium
Novartis
Clinical Trial
Amgen, Sanofi, Servier
Advisory Board or equivalent: Modest Stipend
Amgen, Sanofi, Servier
Speakers Bureau: Modest
Amgen, Sanofi, Servier
received payment for talks
Amgen, Merck
Grants/Honorarium: Modest
NIH Ischemia
Clinical Trial- medical vs revascularization therapy, core CCTA analysis
John Mancini
43
OTTAWA HEART CONFERENCES 2016
Ruth McPherson
Sanofi, Amgen
Advisory Board or equivalent
Sanofi, Amgen
Speakers Bureau
Pfizer, Sanofi
Clinical Trial - Studies on safety and
efficacy of PCSK9 inhibitors
Thierry Mesana
Robert Reid
No disclosures
Pfizer
Speaker Bureau re: smoking
Pfizer, Johnson and Johnson
Grants
Christopher Simpson
National Speakers Bureau
Derek So
Eli-Lilly, Spartan Bioscience Inc
Physician Initiated Grant
Bradley Strauss
Matrizyme Pharma
Founder, member of Board of
Directors; Salary; hold Patent (collagenase patents for chronic total
occlusion); Shares; Clinical Trial
AMGEN, Janssen, Sanofi-Pasteur
Advisory Board
Merck
Speakers Bureau
Servier, Astra Zeneca
Grant
Novartis
Clinical Trial
Astra Zeneca, Boehringer-Ingelheim,
Merck (feel like there is one that got
cut off )
Advisory Board or Equivalent
Astra Zeneca, Boehringer-Ingelheim,
Novo Nordsk
Research Grants to Institution
Novo Nordsk, Boehringer-Ingelheim,
Astra Zeneca
CVD outcome Trials
Sheldon Tobe
Jacob Udell
Bernard Zinman
44
OTTAWA HEART CONFERENCES 2016
Accreditation
This event is an Accredited Group Learning Activity (Section 1) as defined by
the Maintenance of Certification program of the Royal College of Physicians
and Surgeons of Canada for 19.50 hours.
Cette activité est une activité de formation collective agréée aux termes de
la Section 1 du programme de Maintien du certificat du Collège royal des
médecins et chirurgiens du Canada pour 19,50 heures.
This program has also been accredited by the College of Family Physicians of
Canada, for up to 19.50 Mainpro-M1 hours. This program has been reviewed
and approved by the University of Ottawa, Office of Continuing Professional
Development.
Ce programme répond aux critères d’agrément du Collège des médecins de
famille du Canada accorde jusqu’à 19,50 heures Mainpro-M1. Ce programme
a été révisé et approuvé par le Bureau de formation professionnelle continue
de l’Université d’Ottawa.
AMA designation statement:
Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may
convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be
found at www.ama-assn.org/go/internationalcme.
En vertu d’une entente conclue entre le Collège royal des médecins et chirurgiens du Canada et l’American Medical Association, les médecins peuvent
convertir les crédits obtenus au titre du programme de MDC du Collège royal
en crédits de catégorie 1 de l’AMA PRAMC. Vous trouverez l’information sur le
processus de conversion des crédits du programme de MDC du Collège royal
en crédits de l’AMA à l’adresse www.ama-assn.org/go/internationalcme.
45
OTTAWA HEART CONFERENCES 2016
Notes
____________________________________
____________________________________
____________________________________
____________________________________
____________________________________
____________________________________
____________________________________
____________________________________
____________________________________
____________________________________
____________________________________
____________________________________
____________________________________
____________________________________
____________________________________
____________________________________
____________________________________
____________________________________
____________________________________
____________________________________
____________________________________
46
OTTAWA HEART CONFERENCES 2016
i
OTTAWA HEART CONFERENCES 2016
4
th
ANNUAL OTTAWA HEART
ii